XML 57 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Data (Tables)
 6 Months Ended
Mar. 25, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment was as follows:

Three Months Ended
 
Six Months Ended

March 25,
2016

March 27,
2015
 
March 25,
2016
 
March 27,
2015
Net sales:



 
 
 
 
Specialty Brands
$
535.0


$
334.3

 
$
1,078.2

 
$
707.9

Specialty Generics
264.4

 
362.8

 
522.0

 
647.0

Nuclear Imaging
102.2


109.5

 
205.8

 
211.4

Net sales of operating segments
901.6


806.6

 
1,806.0

 
1,566.3

Other (1)
16.4


12.4

 
26.8

 
20.9

Net sales
$
918.0


$
819.0

 
$
1,832.8

 
$
1,587.2

Operating income:



 
 
 
 
Specialty Brands
$
263.1


$
97.4

 
$
535.1

 
$
245.6

Specialty Generics
101.6

 
203.7

 
219.8

 
344.2

Nuclear Imaging
31.1


18.8

 
46.1

 
23.6

Segment operating income
395.8


319.9

 
801.0

 
613.4

Unallocated amounts:





 
 
 
 
Corporate and allocated expenses (2)          
(29.1
)

(99.5
)
 
(75.1
)
 
(139.3
)
Intangible asset amortization
(175.0
)

(122.9
)
 
(348.4
)
 
(247.7
)
Restructuring and related charges, net (3)
(10.4
)

(3.6
)
 
(16.8
)
 
(10.9
)
Non-restructuring impairment charges
(16.9
)
 
—

 
(16.9
)
 
—

Operating income
$
164.4

 
$
93.9

 
$
343.8

 
$
215.5


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
(2)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(3)
Includes restructuring-related accelerated depreciation.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's segments are as follows:
 
Three Months Ended
 
Six Months Ended
 
March 25, 2016
 
March 27, 2015
 
March 25, 2016
 
March 27, 2015
Acthar
$
248.4

 
$
228.0

 
$
535.1

 
$
494.4

Inomax
115.5

 
—

 
226.3

 
—

Ofirmev
71.1

 
68.1

 
138.0

 
139.5

Therakos immunotherapy
50.2

 
—

 
100.6

 
—

Hemostasis products
11.4

 
—

 
11.4

 
—

Other
38.4

 
38.2

 
66.8

 
74.0

Specialty Brands
535.0

 
334.3

 
1,078.2

 
707.9

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
40.8

 
66.6

 
77.5

 
100.6

Oxycodone (API) and oxycodone-containing tablets
37.9

 
48.6

 
66.8

 
95.6

Methylphenidate ER
24.6

 
34.0

 
55.8

 
82.6

Other controlled substances
121.9

 
145.4

 
231.6

 
257.3

Other
39.2

 
68.2

 
90.3

 
110.9

Specialty Generics
264.4

 
362.8

 
522.0

 
647.0

 
 
 
 
 
 
 
 
Nuclear Imaging
102.2

 
109.5

 
205.8

 
211.4

 
 
 
 
 
 
 
 
Other (1)
16.4

 
12.4

 
26.8

 
20.9

Net sales
$
918.0

 
$
819.0

 
$
1,832.8

 
$
1,587.2


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.